Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Revenue (2020 - 2023)

Historic Revenue for Gain Therapeutics (GANX) over the last 4 years, with Q1 2023 value amounting to $55180.0.

  • Gain Therapeutics' Revenue rose 2260.59% to $55180.0 in Q1 2023 from the same period last year, while for Dec 2023 it was $55180.0, marking a year-over-year decrease of 6061.61%. This contributed to the annual value of $55180.0 for FY2023, which is 6061.61% down from last year.
  • Per Gain Therapeutics' latest filing, its Revenue stood at $55180.0 for Q1 2023, which was up 2260.59% from $95102.0 recorded in Q2 2022.
  • In the past 5 years, Gain Therapeutics' Revenue ranged from a high of $95102.0 in Q2 2022 and a low of $5269.0 during Q1 2021
  • Moreover, its 4-year median value for Revenue was $27345.0 (2021), whereas its average is $35378.5.
  • The largest annual percentage gain for Gain Therapeutics' Revenue in the last 5 years was 129923.11% (2021), contrasted with its biggest fall of 2104.0% (2021).
  • Quarter analysis of 4 years shows Gain Therapeutics' Revenue stood at $9139.0 in 2020, then soared by 372.79% to $43208.0 in 2021, then surged by 120.1% to $95102.0 in 2022, then crashed by 41.98% to $55180.0 in 2023.
  • Its last three reported values are $55180.0 in Q1 2023, $95102.0 for Q2 2022, and $45006.0 during Q1 2022.